Almost 40% of Alzheimer’s disease and related dementia (ADRD) risk can be attributed to modifiable factors, indicating the importance of creating scalable strategies to address this risk. MKN shows potential as a non-pharmacologic therapy for reducing modifiable risks related to ADRD.
A modified Mediterranean ketogenic diet has been found to offer added benefits for various biomarkers linked to ADRD, along with cognitive functioning. Learning and following this nutrition type can be difficult and require careful attention to maintain a healthy approach.
In the present study, researchers developed a program to assist older adults with memory issues using MKN.
A two-arm randomized pilot trial recruited individuals from a senior health clinic, local community, and participant registry, aged between 60 and 85 years and having possible mild cognitive impairment. Approximately 109 individuals underwent a telephone screening process to assess their initial eligibility.